Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A non-canonical lymphoblast in refractory childhood T-cell leukaemia.
Lim BSJ, Whitfield HJ, Trinh MK, Bloye G, Thomas R, Anderson ND, Wenger A, Hodder A, Treger TD, Lee-Six H, Coorens THH, Parks C, Ogbonnah T, Pölönen P, Mullighan CG, Teachey DT, Xu J, Tan K, Hagleitner M, Kester L, van Leeuwen FN, Beattie G, Mansour MR, Williams O, Bartram J, Adams S, Jardine L, Behjati S, O'Connor D. Lim BSJ, et al. Among authors: van leeuwen fn. Nat Commun. 2025 Nov 12;16(1):9397. doi: 10.1038/s41467-025-65049-8. Nat Commun. 2025. PMID: 41224801 Free PMC article.
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
Amaral P, Christie R, Gresham DOF, Lucas EJM, Xu LK, Behrmann L, Bond J, Degerman S, van Delft FW, Goossens S, Hagleitner M, Halsey C, Jones N, Lammens T, van Leeuwen FN, Mansour MR, Ntziachristos P, O'Connor D, Barata JT. Amaral P, et al. Among authors: van leeuwen fn. Leukemia. 2025 Nov;39(11):2575-2589. doi: 10.1038/s41375-025-02723-2. Epub 2025 Aug 14. Leukemia. 2025. PMID: 40813621 Review.
CpG island methylator phenotype classification improves risk assessment in pediatric T-cell acute lymphoblastic leukemia.
Schäfer Hackenhaar F, Refhagen N, Hagleitner M, van Leeuwen F, Marquart HV, Madsen HO, Landfors M, Osterman P, Schmiegelow K, Flaegstad T, Jónsson Ó, Kanerva J, Abrahamsson J, Heyman M, Norén Nyström U, Hultdin M, Degerman S. Schäfer Hackenhaar F, et al. Blood. 2025 May 8;145(19):2161-2178. doi: 10.1182/blood.2024026027. Blood. 2025. PMID: 39841000 Free PMC article.
Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Gerritsen M, van der Meer LT, Williams O, Hoogerbrugge PM, Scheijen B, van Leeuwen FN. Tijchon E, et al. Among authors: van emst l, van ingen schenau d, van der meer lt, van leeuwen fn. Exp Hematol. 2018 Apr;60:57-62.e3. doi: 10.1016/j.exphem.2018.01.006. Epub 2018 Feb 8. Exp Hematol. 2018. PMID: 29408281 Free article.
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, Kornblau SM, Farrar MA. Katerndahl CDS, et al. Among authors: van leeuwen fn. Nat Immunol. 2017 Jun;18(6):694-704. doi: 10.1038/ni.3716. Epub 2017 Apr 3. Nat Immunol. 2017. PMID: 28369050 Free PMC article.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. van der Veer A, et al. Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23. Blood. 2013. PMID: 23974192 Free PMC article.
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia.
Vervoort BMT, Butler M, Grünewald KJT, Schenau DSVI, Tee TM, Lucas L, Huitema ADR, Boer JM, Bornhauser BC, Bourquin JP, Hoogerbrugge PM, Van der Velden VHJ, Kuiper RP, Van der Meer LT, Van Leeuwen FN. Vervoort BMT, et al. Among authors: van leeuwen fn. Haematologica. 2024 Dec 1;109(12):3904-3917. doi: 10.3324/haematol.2023.284357. Haematologica. 2024. PMID: 38841778 Free PMC article.
A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.
Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW, Flucke U, van Leeuwen FN, Hoogerbrugge PM, Guchelaar HJ, te Loo DM. Hagleitner MM, et al. Among authors: van der graaf wt, van leeuwen fn. Clin Cancer Res. 2015 Aug 1;21(15):3436-41. doi: 10.1158/1078-0432.CCR-14-2638. Epub 2015 Mar 31. Clin Cancer Res. 2015. PMID: 25829401
Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW. Hagleitner MM, et al. Among authors: van leeuwen fn. PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014. PLoS One. 2014. PMID: 25551397 Free PMC article.
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.
Antić Ž, Yu J, Van Reijmersdal SV, Van Dijk A, Dekker L, Segerink WH, Sonneveld E, Fiocco M, Pieters R, Hoogerbrugge PM, Van Leeuwen FN, Van Kessel AG, Waanders E, Kuiper RP. Antić Ž, et al. Among authors: van reijmersdal sv, van leeuwen fn, van dijk a, van kessel ag. Haematologica. 2021 Dec 1;106(12):3046-3055. doi: 10.3324/haematol.2020.259226. Haematologica. 2021. PMID: 33147938 Free PMC article.
90 results